Head to Head Contrast: Urogen Pharma (NASDAQ:URGN) vs. Pulmatrix (NASDAQ:PULM)

Pulmatrix (NASDAQ:PULM) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Risk and Volatility

Pulmatrix has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Earnings and Valuation

This table compares Pulmatrix and Urogen Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81 million	0.67	-$5.16 million	($1.10)	-1.31
Urogen Pharma	$109.79 million	19.26	-$153.49 million	($1.98)	-21.84

Pulmatrix has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pulmatrix and Urogen Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-125.65%	-95.19%
Urogen Pharma	-51.73%	N/A	-43.79%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pulmatrix and Urogen Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1	0	0	0	1.00
Urogen Pharma	1	1	8	0	2.70

Urogen Pharma has a consensus target price of $52.38, suggesting a potential upside of 21.10%. Given Urogen Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Pulmatrix.

Insider & Institutional Ownership

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Urogen Pharma beats Pulmatrix on 9 of the 14 factors compared between the two stocks.

About Pulmatrix

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.